

# Heparan Sulfate Proteoglycans during Terminal Skeletal Muscle Cell Differentiation: Possible Functions and Regulation of their Expression

Enrique Brandan and Juan Larrain

---

*Department of Cell and Molecular Biology, Faculty of Biological Sciences, Catholic University of Chile, Santiago, Chile*

## Abstract

Heparan sulfate proteoglycans are key molecules found associated with the cell surface and extracellular matrix (ECM). These macromolecules seem to be essential to achieve terminal skeletal muscle differentiation. In this review, we present data about the types of heparan sulfate proteoglycans present in skeletal muscle cells, how their expression changes during differentiation and we propose some mechanisms that might be controlling and/or affecting their expression. Finally, we discuss some possible functions for these heparan sulfate proteoglycans during skeletal muscle differentiation.

**Key words:** myogenesis, proteoglycans, growth factors, cell differentiation, heparan.

Proteoglycans are produced by most eukaryotic cells and are versatile components of pericellular and extracellular matrices (ECM). Proteoglycans are composed of proteins that have one or more chains of sulfated carbohydrates covalently linked, called glycosaminoglycans. Depending on the carbohydrate sequence and sulfation modifications, the glycosaminoglycans can be classified as heparin, heparan sulfate, dermatan sulfate, chondroitin sulfate and keratan sulfate. An increasingly growing list of work focusing on the understanding of their basic structure, biosynthetic pathways and functions is available (see reviews, [6, 18,46,55]).

Heparan sulfate proteoglycans are present on the cell surface and interact with a great variety of compounds, including ECM constituents [29, 49], adhesion molecules [15] and growth factors [6,46]. Some of the heparan sulfate proteoglycans present on the surface can also interact with cytoskeletal components [6, 12] making these molecules key elements in the interaction of the cell with the extracellular environment. These proteoglycans can be associated with the basal lamina, i.e. perlecan or with the plasma membrane via different mechanisms. Those present in the plasma membrane can be anchored by either a transmembrane core protein, for example members of the syndecan family [35, 50] or by a glycosylphosphatidylinositol anchor (GPI), for example glypican [13, 16]. This suggests that the presence of heparan sulfate proteoglycans on the cell surface or ECM may influence the response of a particular cell type to changes in the environment.

*Basic Appl Myol. 8 (2): 107-113, 1998*

This idea is particularly attractive during skeletal muscle cell differentiation. The fusion of mononucleated cells is a central event in terminal differentiation of skeletal muscle. Mononucleated myoblasts undergo a series of events including cell fusion to form multinucleated myotubes together with the synthesis and assembly of myofibrillar proteins to form muscle fibers [19, 61]. *In vitro* studies using skeletal muscle derived cell lines, have shown that inhibition of sulfation of proteoglycans [36] and the presence of basic fibroblast growth factor (bFGF) [9] have a strong inhibitory effect on skeletal muscle differentiation. The signaling pathways that are activated by the binding of bFGF to its receptor have been shown to be heparan sulfate proteoglycan dependent [3]. Thus, skeletal muscle cells treated with heparitinase can undergo normal terminal differentiation, even in the presence of bFGF [44]. Several interesting questions arise from these observations; How many heparan sulfate proteoglycans are present on the surface of myoblasts, and is their expression regulated during skeletal muscle differentiation? What is the specific function of heparan sulfate proteoglycans on the cell surface of skeletal muscle cells?

## Expression of Heparan Sulfate Proteoglycans during Skeletal Muscle Differentiation

Skeletal muscle cells are a useful model for studying cell differentiation. The fusion of mononucleated cells to form multinucleated myotubes is a central event in skeletal muscle development. Controlling the onset and progression of this process is a complex set of interactions between

## Heparan sulfate proteoglycan in skeletal muscle differentiation

myoblasts and their environment. Some of the regulatory proteins that control this process have been identified. Thus, when myogenesis begins, myogenic regulatory genes belonging to the MyoD family (myogenin, *mrf5*, *mrf4*) are activated [19]. These regulatory factors can bind to specific DNA consensus sites called E-boxes, which function as transcriptional enhancers of muscle-differentiation genes (for review see [34]). Recent data suggests that another set of factors the MEF2 family are also required to specify muscle fate or to direct muscle differentiation [37]. The expression and activity of these master genes are regulated by polypeptide growth factors including bFGF [9], transforming growth factor  $\beta$  (TGF- $\beta$ ) [8], insulin-like growth factor (IGF) [56] and hepatocyte growth factor/scatter factor (HGF/SC) [1] as well as by retinoic acid (RA) [22]. One or more of these growth factors, when present as a result of autocrine or paracrine signaling hold myoblasts in the undifferentiated state whereas RA induces myoblast differentiation [22] (see Figure 1).

With respect to changes in the expression of heparan sulfate proteoglycans in skeletal muscle cells, we have studied the expression of glypican, a proteoglycan present in several cell types such fibroblasts [16], Schwann cells [13] and skeletal muscle cells [11]. Glypican has the ability to bind bFGF [52]. Glypican expression is up-regulated during differentiation of a mouse skeletal muscle cell line (C2C12) (Table 1, Fig. 1). Differentiated skeletal muscle cells express glypican on their surface, which can be released by phosphatidylinositol specific phospholipase C (PI-PLC) [11]. Analysis of hydrophobicity revealed that only purified glypican obtained from detergent extracts was able to be incorporated into liposomes, whereas the PI-PLC released form was not, suggesting that the glycosylinositol moiety present in this proteoglycan was essential for association with the plasma membrane [11]. We also found that glypican co-localizes with laminin in adult rat skeletal muscles sections, indicating a possible role for this proteoglycan as a cell receptor for ECM components [11]. This observation is supported by the fact that glypican can bind to immobilized laminin [13].

Perlecan, a multifunctional heparan sulfate proteoglycan, is an intrinsic constituent of basement membranes and




Figure 1. Different heparan sulfate proteoglycans are expressed during skeletal muscle differentiation. Some heparan sulfate proteoglycans are expressed in myoblasts (on the left): SYN, syndecan-1; FG, fibroglycan or syndecan-2; NG, neuroglycan or syndecan-3; RYU, ryoducan or syndecan-4; PER, perlecan. Other are expressed after triggering differentiation (on the right) GLY, glypican. The inhibitory effect of growth factors (bFGF, TGF- $\beta$  and HGF/SF) and stimulatory effect of retinoic acid (RA) on skeletal muscle differentiation is shown.

ECMs [25,55]. It consists of at least five separate domains which include a putative heparan sulfate binding region, a domain homologous to the low density lipoprotein-receptor, a domain similar to the neural cell adhesion molecule, and two domains homologous to regions in laminin [40, 41]. This proteoglycan has the ability to bind bFGF [3]. In contrast to glypican the expression of perlecan during skeletal muscle differentiation is downregulated (Table 1, Fig. 1) [30, 31]. Perlecan is present on the myoblasts surface, associated with an incipient ECM [30, 31]. Interestingly it was been shown by *in situ* hybridization studies, using a probe encoding domain 111 of perlecan, that perlecan mRNA was absent in human adult skeletal muscle, consistent with our findings [40].

The best characterized cell surface proteoglycans are the syndecans, a family of at least four transmembrane heparan sulfate proteoglycans that are implicated in a

Table 1. Changes in the expression of heparan sulfate proteoglycans during skeletal muscle differentiation.

PROTEOGLYCAN	INCREASE	DECREASE	UNCHANGE
SYNDECAN-1 [33]		XXX	
FIBROGLYCAN (unp. observation)			X
NEUROGLYCAN (unp. observation)		XXX	
RYODUCAN (unp. observation)		X	
PERLECAN [29]		XXX	
GLYPLICAN [47]			
XXX - strong change; X = weak change.	XXX		

## Heparan sulfate proteoglycan in skeletal muscle differentiation

variety of interactions with the pericellular microenvironment, (for reviews see [6, 18]). Syndecans bind a variety of ECM constituents, such as fibronectin [49], thrombospondin [54], tcnascin [48] and collagen types I, III and V [29] as well as bFGF [28]. We have evaluated the expression of syndecan-1 [32], neuroglycan (syndecan-3) and ryoducan (syndecan-4) (Brandan et al., manuscript in preparation) during skeletal muscle differentiation. In this case we have found that the expression of syndecan-1, -3 and -4 is down regulated (Table I, Fig. 1). In contrast the expression of fibroglycan (syndecan-2) (Brandan et al., manuscript in preparation) seems to be constitutive throughout differentiation (Table I, Fig. 1).

### Possible Mechanisms Involved in the Regulated Expression of Heparan Sulfate Proteoglycans during Differentiation

Analysis of published promoter regions for heparan sulfate proteoglycans [2, 14, 23, 64] have revealed several interesting putative binding sites for transcription factors. These are presented in Table II,

Glypican, the only heparan sulfate proteoglycans which increases its expression during skeletal muscle differentiation, contains several E-boxes, putative target sites for the action of myogenic regulators such MyoD and myogenin [42], as well as sites for NF-KB and SP1 in the promoter region [2]. Because E-boxes function as transcriptional enhancers of muscle differentiating genes, it is tempting to speculate that myogenin or a related skeletal muscle transcriptional factors might be directly involved in the up-regulated expression of glypican observed during differentiation. Alternatively, it is possible to speculate that the expression of glypican increases during differentiation as a consequence of the removal of growth factors. Consistent with this idea is the fact that the synthesis of glypican by human lung fibroblasts is down regulated by the presence of BFGF and TGF- $\beta$  [45].

It has been suggested that the mechanism(s) responsible for the downregulation of syndecan-1 expression during muscle differentiation is the presence of E-boxes in the promoter region of syndecan-1 [5]. We have evaluated the participation of two E-boxes in the promoter region of the syndecan-1 gene, by transiently transfecting myoblasts with CAT reporter vectors containing a portion of the rat syndecan-1 promoter that contain or lack the E-boxes. Our

Table II. Presence of different regulatory elements in the promoter region of heparan sulfate proteoglycans.

PROTEOGLYCAN	REGULATORY ELEMENT
SYNDECAN-1	E-Box, Aintenedia, SP1, NF-KB, RARE [34]
PERLECAN	SPI, TATA box absent [35]
GLYPICAN	E-Box, SP1, NF-KB, TATA box absent [37]
SYNDECAN-4	SPI, TATA box, NF-KB [36]

results clearly demonstrate that in this case the presence of the E-boxes is not required for the decrease in expression of syndecan-1 that is observed after differentiation is triggered. These results are also supported by the finding that treatment of differentiating myoblasts with sodium butyrate, an agent known to inhibit myogenin expression [20, 26], did not affect the pattern of syndecan-1 expression during differentiation. These results are not surprising in the sense that the expression of genes regulated by myogenin are usually up-regulated and as discussed, the expression of syndecan-1 was down-regulated. We have also found that promoter activity of syndecan-1 was not significantly affected by BFGF or TGF- $\beta$ . However exposure to both growth factors resulted in a significant increase in syndecan-1 gene activity. Treatment of the cells with RA, an inducer of skeletal muscle differentiation [22], had an inhibitory effect on the expression of syndecan-1 reporter. To date only TNF- $\alpha$  has been shown to decrease expression of syndecan-1 in endothelial cells [27]. Furthermore, RA was able to abolish the stimulatory effect observed after treatment of myoblasts with BFGF and TGF- $\beta$  and fetal calf serum [32]. This is particularly interesting because both growth factors and RA are known to be present in the vicinity of condensing mesenchymal cells [57] and limb buds during early developmental stages [38].

These results indicate that the main regulatory elements responsible for the transcriptional regulation of syndecan-1 expression during myoblast differentiation are contained in the proximal 277 bp segment of the syndecan-1 promoter. The inhibitory effect of RA on syndecan-1 expression could be explained by the presence of putative RA responsive elements (RAREs) in the promoter region. These are located 55,80 and 100 bp upstream of the TATA box [2, 1]. This sequence is sufficient to cause the inhibitory effect of RA on the murine Oct4 promoter [51].

As seen in Table II perlecan lacks canonical TATA box and CAAT boxes, but several SPI transcription factor binding sites are present within the promoter region of perlecan [14] which resembles that of mouse syndecan-1. These observations suggest that similar regulatory mechanisms (e.g. growth factors and retinoic acid) may be involved in the regulation of expression of these cell surface macromolecules during differentiation of skeletal muscle cells. These observations are attractive because it may imply that common mechanisms are participating in the regulation of these two different proteoglycans, and that the coordinate regulation indicates a similar function. If this is the case, then it is appropriate to inquire about the specific function that these two proteoglycans may play during differentiation of skeletal muscle (see below).

Therefore, the presence or availability of growth factors to interact with skeletal muscle cells during differentiation, and the growth factors that are removed in order to trigger differentiation [7], could influence the level of expression of different proteoglycans. The expression of perlecan and syndecan-1 would be dependent on BFGF and TGF- $\beta$ , whereas glypican expression would be inhibited by the

## Heparan sulfate proteoglycan in skeletal muscle differentiation

factors. Alternatively, downregulation of perlecan and syndecan-1, could be explain by the presence of SP1 binding sites in both promoters. Recently it has been shown that SP1 is downregulated by MyoD during differentiation [59].

### Potential Functions of Heparan Sulfate Proteoglycans during Skeletal Muscle Differentiation

The presence of heparan sulfate proteoglycans are necessary for the modulation of terminal myogenesis [44], probably by acting as low affinity receptors for bFGF [3, 63] or HGF/SF [65], potents inhibitors of myogenesis [1, 9]. The specific action of both growth factors is to inhibit the expression of myogenin, a master gene required for the expression of several skeletal muscle specific genes [42, 53, 61]. The function of syndecan-1 and perlecan in myoblasts and the consequences of their down regulation during differentiation are not known. It is well known that proliferation of myoblasts is strongly stimulated by bFGF and HGF/SF. At the same time these growth factors are strong inhibitor of skeletal muscle differentiation [1,9]. On the other hand, it has been shown that heparan sulfate proteoglycans act as co-receptors for bFGF [63], and HGF/SF [65, 47] allowing the binding of the growth factors to its signaling receptor on the plasma membrane and stimulating its biological effects. Therefore, the presence of syndecan-1 and/or perlecan in the membrane may facilitate bFGF and HGF/SF binding to its receptors. When differentiation is triggered, regulatory mechanisms as mentioned above, could inhibit the expression of syndecan-1 and/or perlecan, together with the expression of bFGF receptor [39] and c-met receptor [1], resulting in a decrease or loss of the capability of bFGF and HGF/SF to bind to their receptors activating differentiation of skeletal muscle cells through a myogenin dependent pathway.

It has been shown that ncrlecan, but not syndecan-1, -2, -3 or glypican, when added to culture medium is able to bind bFGF and promote biological activity [3]. On the other hand, overexpression of recombinant membrane associated heparan sulfate proteoglycans (syndecan-1, -2, -4 and glypican) can act as low affinity receptors for bFGF in a hematopoietic cell line that expresses low levels of heparan sulfate proteoglycan [52]. Experiments designed to maintain constitutive syndecan-1 and/or perlecan expression and to abolish their expression in myoblasts are in progress. This experimental approach will specifically evaluate the participation of this proteoglycan as a growth factor co-receptor.

The expression of glypican is enhanced during differentiation. This proteoglycan is present in the surface of skeletal muscle cells and is processed to a soluble form that is incorporated in the ECM [7]. In transverse sections of skeletal muscle, it co-localized with laminin in the basal lamina surrounding individual muscle fibers [11], It has been postulated that this proteoglycan sequesters bFGF after differentiation has been initiated, preventing the inhibitory effect of bFGF on myogenin expression. Immo-

lized bFGF then may be released from the ECM by specific proteases [62] when proliferation of satellite skeletal muscle cells is necessary; e.g. in the case of skeletal muscle regeneration following injury. We have demonstrated that glypican is released from the plasma membrane into the incubation medium by an endogenous mechanism, likely to be a phospholipase mediated [7]. Interestingly, it has been shown that treatment of endothelial cells, smooth muscle cells and bone marrow cultures with glycosylphosphatidylinositol-specific phospholipase C, released a cell surface associated bFGF bound to heparan sulfate proteoglycan [4, 10]. Therefore, it is possible that one of the functions of glypican in skeletal muscle cells is to sequester bFGF and HGF/SF after differentiation has been triggered, and to liberate it after muscle damage. Figure 2, indicates a model whereas heparan sulfate proteoglycans may be acting as presenters of growth factors to bFGF and HGF/SF to their transducing receptors (FGFR-1 and c-met) in myoblasts but sequesters for them after triggering differentiation.

Another potential role for the presence of heparan sulfate proteoglycans on the surface of myoblasts is to bind ECM adhesive proteins. We have demonstrated that treatment of skeletal muscle cells induced to differentiate with chlorate has a strong inhibitory effect on the organization of the ECM, and an inhibition of differentiation [36]. The inhibitory effect on differentiation can be abolished by adding exogenous ECM even in the presence of chlorate [36]. These results suggest that proteoglycans are required for an appropriate organization of the ECM which is needed to achieve the complete differentiation of skeletal muscle cells. Syndecan-1 has been shown to bind several ECM




Figure 2. Heparan sulfate proteoglycans are modulators of myogenesis. Heparan sulfate proteoglycans can be acting as growth factors presenters to their transducing receptors (FGFR-1, c-met) (on the left) or as growth factor sequesters by concentrating them in the extracellular matrix (ECM) (on the right). Heparan sulfate proteoglycans are indicated accordingly to the legend of Figure 1.

## Heparan sulfate proteoglycan in skeletal muscle differentiation

adhesive molecules, including fibronectin [49], thrombospondin [54], tenascin [48] and collagen types I, III and V [29]. Cell adhesion to these matrix proteins might not be required following differentiation when individual muscle fibers are in direct contact with basement membrane ECM. Furthermore, it has been shown that syndecan-1 can influence cell invasion [33]. Myoblasts are able to migrate through basal lamina during early stages of differentiation [24]. It is tempting to speculate that the presence of syndecan-1 on the surface of myoblasts may influence their migratory pathway to give rise slow or fast primary myotubes [58]. One attractive ECM candidate directly involved in skeletal muscle differentiation is laminin. This glycoprotein promotes myogenesis in rat skeletal muscle cultures [21, 60], its expression [43] as well as one of its cellular receptors,  $\alpha 1$  integrin, is up-regulated during differentiation [17]. Interestingly, glypican, is able to interact with laminin [13]. Perhaps the interaction between laminin and glypican or another heparan sulfate proteoglycan may be required to achieve terminal myogenesis.

### Acknowledgments

This work was supported in part by grants from FONDECYT (1960634) to E.B. and (2960045) to J.L. The research of E.B. was supported in part by an International Research Scholars grant from the Howard Hughes Medical Institute. J.L. is a doctoral fellowship recipient from Fundacion Andes.

### Address correspondence to:

E. Brandan, Departamento de Biología Celular y Molecular, Facultad de Ciencias Biológicas, P. Universidad Católica de Chile, Casilla 114-D, Santiago, Chile, fax 56 26862717, Email ebrandan@genes.bio.puc.cl@.

### References

- [1] Anastasi S, Giordano S, Sthandier O, Gambarotta G, Maione R, Comoglio P, Amati P: A natural hepatocyte growth factor/scatter factor autocrine loop in myoblast cells and the effect of the constitutive Met kinase activation on myogenic differentiation. *J Cell Biol* 1997; 137: 1057-1065.
- [2] Asundi VK, Keister BF, Carey DJ: Rat glypican exon I sequence. *GenBank Database*. U82702 1996.
- [3] Aviezer D, Hecht D, Safran M, Eisinger M, David G, Yayon A; perlecan, basal lamina proteoglycan, promotes basic fibroblast growth-receptor binding, mitogenesis, and angiogenesis. *Cell* 1994; 79: 1005-1013.
- [4] Bashkin P, Neufeld G, Gitay-Goren H, Vlodavsky I: Release of cell surface-associated basic fibroblast growth factor by glycosylphosphatidylinositol-specific phospholipase C *J Cell Physiol* 1992; 151: 126-137.
- [5] Bernfield M, Hinkes MT, Gallo RL: Developmental expression of the syndecans: possible function and regulation. *Development* 1993; Supplement: 205-212.
- [6] Bernfield M, Kokenyesi R, Kato M, Hinkes MT, Spring J, Gallo RL, Lose EJ: Biology of syndecans: A family of transmembrane heparan sulfate proteoglycans. *Annu Rev Cell Biol* 1992; 8: 365-393.
- [7] Brandan E, Carey DJ, Larrain J, Melo F, Campos A: Synthesis and processing of glypican during differentiation of skeletal muscle cells. *Eur J Cell Biol* 1996; 71: 170-176.
- [8] Brennan TJ, Edmondson DG, Li L, Olson EN: Transforming growth factor beta represses the actions of myogenin through a mechanism independent of DNA binding. *Proc Natl Acad Sci USA* 1991; 88: 3822-3826.
- [9] Brunetti A, Goldfine ID: Role of myogenin in myoblast differentiation and its regulation by fibroblast growth factor. *J Biol Chem* 1990; 265: 5960-5963.
- [10] Brunner G, Gabrilove J, Rifkin DB, Wilson EL: Phospholipase C release basic fibroblast growth factor from human bone marrow cultures as a biologically active complex with a phosphatidylinositol-anchored heparan sulfate proteoglycan. *J Cell Biol* 1991; 114: 1275-1283.
- [11] Campos A, Nufiez R, Koenig CS, Carey DJ, Brandan E: A lipid anchored heparan sulfate proteoglycan is present in the surface of differentiated skeletal muscle cells: Isolation and biochemical characterization. *Eur J Biochem* 1993; 216: 587-595.
- [12] Carey D, Stahl RC, Cizmeci-Smith G, Asundi VK: Syndecan-1 expressed in schwann cells cause morphological transformation and cytoskeletal reorganization and associates with actin during spreading. *J Cell Biol* 1994; 124: 181-170.
- [13] Carey DJ, Stahl RC: Identification of a lipid-anchored heparan sulfate proteoglycan in Schwann cells. *J Cell Biol* 1990; 111: 2053-2062.
- [14] Cohen IR, Grassel S, Murdoch AD, Iozzo RV: Structural characterization of the complete human perlecan gene and its promoter. *Proc Natl Acad Sci USA* 1993; 90: 10404-10408.
- [15] Cole OJ, Burg M: Characterization of heparan sulfate proteoglycan that copurifies with neural cell adhesion molecule. *Exp Cell Res* 1989; 182: 44-60.
- [16] David G, Lories V, Decock B, Marynen P, Cassiman JJ, Vanden Berghe H: Molecular cloning of a phosphatidylinositol-anchored heparan sulfate proteoglycan from human lung fibroblasts. *J Cell Biol* 1990; 111: 3165-3176.

## Heparan sulfate proteoglycan in skeletal muscle differentiation

- [17] Dubancl JL, Beikin AM, Syfrig J, Thiery JP, Koteliensky VE: Expression of alpha 1 integrin, a laminin-collagen receptor, during myogenesis and neurogenesis in the avian embryo. *Development* 1992; 116:585-600.
- [18] Elenius K, Jalkanen M: Function of the syndecans - a family of cell surface proteoglycans. *J Cell Sci* 1994; 107:2975-2982.
- [19] Emerson CP: Myogenesis and developmental control genes. *Curr Opin Cell Biol* 1990; 2:1065-1075.
- [20] Fiszman MY, Montorras D, Wright W, Gros F: Expression of myogenic differentiation and myo-tube formation by chick embryo myoblasts in the presence of sodium butyrate. *Exp Cell Res* 1980; 126:31-37.
- [21] Foster RF, Thompson JM, Kaufman SJ: A laminin substrate promotes myogenesis in rat skeletal muscle cultures: analysis of replication and development using antidesmin and antiBrUrd monoclonal antibodies. *Dev Biol* 1987; 122: 11-20.
- [22] Halevy O, Lerman O: Retinoic acid induces adult muscle cell differentiation mediated by the retinoic acid receptor- $\alpha$ . *J Cell Biol* 1993; 154:566-572.
- [23] Hinkes MT, Goldberger OA, Neumann PE, Kokenyeci R, Bernfield M: Organization and promoter activity of the mouse syndecan-1 gene. *J Biol Chem* 1993; 268: 11440-11448.
- [24] Hughes SM, Blau HM: Migration of myoblasts across basal lamina during skeletal muscle development. *Nature* 1990; 345: 350-353.
- [25] Iozzo R, Cohen IR, Grissel S, Murdoch AD: The biology of perlecan: the multifaceted heparan sulphate proteoglycan of basement membranes and pericellular matrices. *Biochem J* 1994; 302: 625-639.
- [26] Johnston EA, Tapscott SJ, Eisen H: Sodium butyrate inhibits myogenesis by interfering with the transcriptional activation function MyoD and myogenin. *J Cell Biol* 1992; 12:5123-5130.
- [27] Kainulainen V, Nelimarkka L, Jarvelainen H, Laato M, Jaijgkanen M, Elenius K: Suppression of syndecan-1 expression in endothelial cells by tumor necrosis factor- $\alpha$ . *J Biol Chem* 1996; 271: 18759-18766.
- [28] Kiefer MC, Stephens JC, Crawford K, Okino K, Barr PJ: Ligand-affinity cloning and structure of a cell surface heparan sulfate proteoglycan that binds basic fibroblast growth factor. *Proc Natl Acad Sci USA* 1990; 87: 6985-6989.
- [29] Koda IE, Rapraeger A, Bernfield M: Heparan sulfate proteoglycan from mouse mammary epithelial cell, cell surface proteoglycan as receptor for interstitial collagens. *J Biol Chem* 1985; 260: 8157-8162.
- [30] Larrain J, Alvarez J, Brandan E: The expression of perlecan is down regulated during skeletal muscle differentiation. *Mol Biol Cell* 1996; 7: 237a.
- [31] Larrain J, Alvarez J, Hassell JR, Brandan E: Expression of perlecan, a proteoglycan that binds myogenic inhibitory basic fibroblast growth factor, is down regulated during skeletal muscle differentiation. *Exp Cell Res* 1997; 234: 405-412.
- [32] Larrain J, Cizmeci-Smith G, Troncoso V, Stahl RC, Carey DJ, Brandan E: Syndecan-1 expression is downregulated during myoblasts terminal differentiation: Modulation by growth factors and retinoic acid. *J Biol Chem* 1997; 272: 18418-18424.
- [33] Liebersbach BF, Sanderson RD: Expression of syndecan-1 inhibits cell invasion into type 1 collagen. *J Biol Chem* 1994; 269: 20013-20019
- [34] Emond DC, Konieczny SF: Transcription factor families: muscle in on the myogenic program. *FASEB J* 1995; 9: 1595-1604.
- [35] Marynen PJ, Zhang H, Cassiman JJ, Van den Berghe, David G: Partial primary structure of the 48-and 90-kilodalton core proteins of cell-surface associated heparan sulfate proteoglycan of lung fibroblasts. *J Biol Chem* 1989; 264: 7017-7024,
- [36] Melo F, Carey DJ, Brandan E: Extracellular matrix is required for skeletal muscle differentiation but not myogenin expression. *J Cell Biochem* 1996; 62: 227-239.
- [37] Molkenkin JD, Black BE, Martin JF, Olson EN: Cooperative activation of muscle gene expression by MEF2 and myogenic BHLH proteins. *Cell* 1995; 83: 1125-1136.
- [38] Monioi T, Miyagawa-Tomita S, Kimura I, Momoi M: Retinoic acid ambivalently regulates the expression of MyoD in the myogenic cells in the limb of the early developmental stages. *Biochem Biophys Res Commun* 1992; 187: 245-253.
- [39] Moore JW, Jaye DCM, Swain JL: The mRNAs encoding acidic FGF, basic BFGF and FGF receptor are coordinately downregulated during myogenic differentiation. *Development* 1991; 111: 741-748.
- [40] Murdoch AD, Liu B, Schwarting R, Tuan RS, Irv: Widespread expression of perlecan proteoglycan in basement membranes and extracellular matrices of human tissues as detected by a novel monoclonal antibody against domain 111 and by in situ hybridization. *J Histochem Cytochem* 1994; 42: 239-249.
- [41] Noonan DM, Fuller A, Valente P, Cai S, Horigan E, Sasaki M, Yamada Y, Hassell JR: The complete sequence of perlecan, a basement membrane heparan sulfate proteoglycan, reveals extensive similarity with laminin A chain, low density lipoprotein receptor, and the neural cell adhesion molecule. *J Biol Chem* 1991; 266:22939-22947.

## Heparan sulfate proteoglycan in skeletal muscle differentiation

- [42] Olson EN: MyoD family: a paradigm for development? *Genes Dev* 1990; 4: 1454-1461.
- [43] Olwin BB, Hall ZW: Developmental regulation of laminin accumulation in the extracellular matrix of a mouse muscle cell line. *Dev Biol* 1985; 112: 359-367.
- [44] Rapraeger AC, Krufka A, Olwin BB: Requirement of heparan sulfate for bFGF-mediated fibroblast growth factor and myoblast differentiation. *Science* 1991; 251: 1705-1708.
- [45] Romaris M, Bassols A, David G: Effect of transforming growth factor-beta 1 and basic fibroblast growth factor on the expression of cell surface proteoglycans in human lung fibroblasts. Enhanced glycosylation and fibronectin-binding of CD44 proteoglycan, and down-regulation of glypican. *Biochem J* 1995; 310:73-81.
- [46] Ruoslahti E, Yagamuchi Y: Proteoglycans as modulators of growth factor activities. *Cell* 1991; 64: 867-869.
- [47] Sakata H, Stahl SJ, Taylor WG, Rosenberg JM, Sakaguchi K, Wingfield PT, Rubin JS: Heparin binding and oligomerization of hepatocyte growth factor/scatter factor isoforms. Heparan sulfate glycosaminoglycan requirement for Met binding and signaling. *J Biol Chem* 1997;272: 9457-9463.
- [48] Salmivirta M, Elenius K, Vainio S, Hofer U, Chiquet-Ehrismann R, Thesleff I, Jalkanen M: Syndecan from embryonic tooth mesenchyme binds tenascin. *J Biol Chem* 1991; 266: 7733-7739.
- [49] Saunders S, Bernfield M: Cell surface proteoglycan binds mouse mammary epithelial cells to fibronectin and behaves as a receptor for interstitial matrix. *J Cell Biol* 1988; 106: 423-430.
- [50] Saunders S, Jalkanen M, O'Farrell S, Bernfield M: Molecular cloning of syndecan, an integral membrane proteoglycan. *J Cell Biol* 1989; 108: 1547-1556.
- [51] Schoorlemmer J, van Puijenbroek A, van Den Eijden M, Jonk L, Pals C, Kruijer K: Characterization of a negative retinoic acid response element in the murine Oct4 promoter. *Mol Cell Biol* 1994; 14:1122-1136.
- [52] Steinfeld R, Van Den Berghe H, David G: Stimulation of fibroblast growth factor receptor-1 occupancy and signaling by cell surface-associated syndecans and glypican. *J Cell Biol* 1996; 133: 405-416.
- [53] Stockdale FE: Myogenic cell lineages. *Dev Biol* 1992; 154: 284-298.
- [54] Sun X, Mosher DF, Rapraeger A: Heparan sulfate-mediated binding of epithelial cell surface proteoglycan to thrombospondin. *J Biol Chem* 1989; 264: 2885-2889.
- [55] Timpl R: Proteoglycans of basement membranes. *Experientia* 1993; 49: 417-428.
- [56] Tollefsen SE, Lajara R, McCusker RH, Clemmons DR, Rotwein P: Insulin-like growth factors (IGF) in muscle development. Expression of IGF-1, The IGF-I receptor, and a IGF binding protein during myoblast differentiation. *J Biol Chem* 1989; 264: 13810-13817.
- [57] Vaahtokari A, Vainio S, Thesleff I: Associations between transforming growth factor beta 1 RNA expression and epithelial-mesenchymal interactions during tooth morphogenesis. *Development* 1991; 113:985-994.
- [58] Van Swearingen J, Lance-Jones C: Slow and fast muscle fibers are preferentially derived from myoblasts migrating into the chick limb bud at different developmental times. *Dev Biol* 1995; 170: 321-337.
- [59] Vinals F, Fandos C, Santalucia T, Ferre J, Testar X, Palacin M, Zorzano A: Myogenesis and MyoD down-regulate Sp1. A mechanism for the repression of GLUT 1 during muscle cell differentiation. *J Biol Chem* 1997; 272: 12913-12921.
- [60] Von der Mark K, Ocalan M: Antagonistic effects of laminin and fibronectin on the expression of the myogenic phenotype. *Differentiation* 1989; 40: 150-157.
- [61] Weintraub H: The myoD family and myogenesis: redundancy, networks and thresholds. *Cell* 1993; 75: 1241-1244.
- [62] Whitelock JM, Murdoch AD, Iozzo RV, Underwood A: The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase plasmin, and heparanases. *J Biol Chem* 1996; 271: 10079-10086.
- [63] Yayon A, Klagsbrun M, Esko JD, Leder P, Ornitz DM: Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. *Cell* 1991; 64:841-848.
- [64] Yu H, Humphries DE, Watkins M, Karlinsky JB: Molecular cloning of human ryoducan promoter. *Biochem Biophys Res Commun* 1995; 212: 1139-1144.
- [65] Zioncheck TF, Richardson L, Liu J, Chang L, King KL, Bennett G, Fugedi P, Chamow SM, Schwall RH, Stack RJ: Sulfated oligosaccharides promote hepatocyte growth factor association and govern its mitogenic activity. *J Biol Chem* 1995;270: 16871-16878.